Timing of folic acid/vitamin B12 supplementation and hematologic toxicity during first-line treatment of patients with nonsquamous non-small cell lung cancer using pemetrexed-based chemotherapy: The PEMVITASTART randomized trial.
Navneet SinghMilind BaldiJyotdeep KaurValliappan MuthuKuruswamy T PrasadDigambar BeheraAmanjit BalNalini GuptaRakesh KapoorPublished in: Cancer (2019)
Simultaneous B12-FAS initiation with a pemetrexed-platinum doublet chemotherapy regimen is feasible and does not lead to enhanced hematologic toxicity. Serum homocysteine levels are unaffected by 5 to 7 days of B12-FAS.